PRO-seq of THP-1 cells treated with LSD1 inhibitor INCB059872

INCB059872 is a selective irreversible inhibitor of Lysine-Specific Demethylase 1 (LSD1) that is in phase 1 clinical trials in hematopoietic malignancies. We used precision nuclear run-on sequencing (PRO-seq) to define early transcriptional changes associated with INCB059872 treatment. Changes in nascent transcription could be traced back to a loss of CoREST activity resulting in activation of GFI1-regulated targets. THP-1 cells were treated (in duplicate) with 25nM INCB059872 for 0, 6, 12, or 24hrs. PRO-seq was used to measure changes in nascent transcription.